Research And Development
Medical Devices
Medical

TransEnterix

$1.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (4.13%) Today
-$0.02 (-1.59%) After Hours

Why Robinhood?

You can buy or sell TransEnterix and other stocks, options, ETFs, and crypto commission-free!

About

TransEnterix, Inc., also called TransEnterix, is a medical device company. It focuses on commercialization of Senhance System, that digitizes laparoscopic minimally invasive surgery. Read More It offers the Senhance Surgical Robotic System, which offers robotic surgery for laparoscopic abdominal and pelvic surgery, as well as limited thoracic operations excluding cardiac and vascular surgery, and the SurgiBot System which refers to the a single-port, robotically enhanced laparoscopic surgical platform. The company was founded by William N. Starling in 2006 and is headquartered in Morrisville, NC.

Employees
189
Headquarters
Morrisville, North Carolina
Founded
2006
Market Cap
273.57M
Price-Earnings Ratio
ā€”
Dividend Yield
0.00
Average Volume
4.90M
High Today
$1.27
Low Today
$1.21
Open Price
$1.21
Volume
468.61K
52 Week High
$6.98
52 Week Low
$1.03

Collections

Research And Development
Medical Devices
Medical
Health
US
North America

News

Yahoo FinanceMay 10

Why TransEnterix Is Cratering Today

What happened Shares of the robotic surgery company TransEnterix (NYSEMKT: TRXC) dropped by as much as 29.4% in pre-market trading Friday in response to the company's rough first-quarter earnings report, which it released after the closing bell Thursday. Not only did the company miss Wall Street's consensus estimate for its non-GAAP EPS by 10%, it also whiffed on revenue by a staggering 62% for the period. In fact, TransEnterix's sales fell by 54% in Q1 compared to the same period a year ago. That's a ste...

7,595
Seeking AlphaMay 9

TransEnterix, Inc. CEO Todd Pope on Q1 2019 Results - Earnings Call Transcript

TransEnterix, Inc. (NYSEMKT:TRXC) Q1 2019 Results Conference Call May 9, 2019 4:30 PM ET Company Participants Mark Klausner - Investor Relations Todd Pope - President and Chief Executive Officer Joe Slattery - Executive Vice President and Chief Financial Officer Conference Call Participants Rick Wise - Stifel Jeffrey Cohen - Ladenburg Larry Keusch - Raymond James Operator Good afternoon, ladies and gentlemen. And welcome to the TransEnterix First Quarter 2019 Financial and Operating Results Confer...

2,686
Yahoo FinanceMay 9

Were Hedge Funds Right About Dumping Transenterix Inc ?

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of December.

2,421

Earnings

-$0.09
-$0.08
-$0.07
-$0.06
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
ā€”
Actual
Expected Aug 6, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.